The European Medicines Agency has updated the Q&A document on how companies should go about identifying, redacting, anonymizing and submitting clinical trial documents ahead of the phased re-start of its landmark transparency policy in September.
EMA Prepares To Re-Start ‘Updated’ Clinical Data Publication Policy
The European Medicines Agency has issued revised guidance on its Clinical Data Publication policy to help companies navigate procedural changes that will be introduced when the publication of clinical trial data on non-COVID-19 products is partially resumed under the policy from September 2023.
More from Europe
More from Geography
• By
In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.
• By
Europe’s vaccines industry wants to make sure immunizations “are not forgotten” by policymakers who are overseeing the EU Health Technology Assessment Regulation. It has highlighted several nuances of vaccines that should be addressed over the coming years.
• By
A new chapter that will be published in the European Pharmacopoeia soon is expected to provide a comprehensive framework for the production and quality control of cell-based preparations. Meanwhile, an existing chapter has been revised to facilitate the implementation of rapid microbiological testing methods.